摘要OBJECTIVE: To investigate the effects of Maixuekang Capsules combined with edaravone on serum matrix metalloproteinase-9 (MMP-9), S-100β protein levels and neurological functions in patients with hemorrhagic cerebral infarction. METHOSDS: A total of 76 patients with hemorrhagic cerebral infarction treated in the First Affiliated Hospital of Henan University of Science and Technology from January 2017 to May 2018 were selected and were randomly divided into treatment group and control group, with 38 patients in each group. The control group was given edaravone, and the treatment group was given Maixuekang Capsules on the basis of the control group. The clinical efficacy, serum MMP-9 and S-100β protein levels, neurological function recovery, activity of daily living and incidence rate of adverse reactions were compared between the 2 groups. RESULTS: The total effective rate of the treatment group was 92.11％, which was higher than 71.05％ of the control group (P < 0.05); the National Institutes of Health Stroke Scale (NIHSS) score in the 2 groups decreased (P < 0.05), and the Activity of Daily Living Scale (ADL) score increased (P < 0.05), the improvement of the above 2 scores in the treatment group were better than those in the control group (P < 0.05); the level of MMP-9 was gradually decreasing in the 2 groups, on the 7th day, 14th day after treatment, and the levels of MMP-9 decreased significantly (P < 0.05), and the treatment group was lower than the control group at all time points (P < 0.05); on the 3rd day after treatment, the levels of S-100β protein in the 2 groups increased significantly (P < 0.05); on the 7th day, 14th day after treatment, the levels of S-100β protein in the two groups decreased significantly (P < 0.05), and the treatment group was significantly lower than the control group (P < 0.05); there was no significant difference in incidence rate of adverse reactions between 7.89％ in the control group and 5.26％ in the treatment group (P > 0.05). CONCLUSION: The combination of Maixuekang Capsules and edaravone is effective in treating hemorrhagic cerebral infarction, and it can significantly improve neurological function defect and daily living ability, reduce serum MMP-9 and S-100β protein levels, and has higher safety.